JP2014207903A5 - - Google Patents

Download PDF

Info

Publication number
JP2014207903A5
JP2014207903A5 JP2014083444A JP2014083444A JP2014207903A5 JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5 JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014083444 A JP2014083444 A JP 2014083444A JP 2014207903 A5 JP2014207903 A5 JP 2014207903A5
Authority
JP
Japan
Prior art keywords
cancer
vector
pharmaceutical composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014083444A
Other languages
English (en)
Japanese (ja)
Other versions
JP5767733B2 (ja
JP2014207903A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014207903A publication Critical patent/JP2014207903A/ja
Publication of JP2014207903A5 publication Critical patent/JP2014207903A5/ja
Application granted granted Critical
Publication of JP5767733B2 publication Critical patent/JP5767733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014083444A 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法 Active JP5767733B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90423607P 2007-02-28 2007-02-28
US60/904,236 2007-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009551830A Division JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Publications (3)

Publication Number Publication Date
JP2014207903A JP2014207903A (ja) 2014-11-06
JP2014207903A5 true JP2014207903A5 (https=) 2015-05-14
JP5767733B2 JP5767733B2 (ja) 2015-08-19

Family

ID=39650527

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法
JP2014083444A Active JP5767733B2 (ja) 2007-02-28 2014-04-15 ブラキュリポリペプチドおよび使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009551830A Active JP5596980B2 (ja) 2007-02-28 2008-02-27 ブラキュリポリペプチドおよび使用方法

Country Status (7)

Country Link
US (3) US8188214B2 (https=)
EP (3) EP2125868B1 (https=)
JP (2) JP5596980B2 (https=)
AU (1) AU2008221383B2 (https=)
CA (1) CA2678404C (https=)
DK (1) DK2918598T3 (https=)
WO (1) WO2008106551A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5940554B2 (ja) * 2010-12-09 2016-06-29 アンスティテュ・パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ 高収量の組換えタンパク質発現を得るためのｍｇｍｔに基づく方法
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
WO2014043518A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
JP6851364B2 (ja) 2015-07-31 2021-03-31 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスにおける発現を増強するためのプロモーター
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
EP4137150A1 (en) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
JP2019521099A (ja) * 2016-06-03 2019-07-25 エトゥビクス コーポレーション Ｈｅｒ２／ｎｅｕを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法
CA3026342A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
JP7340458B2 (ja) 2017-05-09 2023-09-07 アメリカ合衆国 Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ
IL292346B2 (en) 2019-11-05 2025-02-01 Apeel Tech Inc Predicting contamination in plant products
WO2022187963A1 (en) * 2021-03-10 2022-09-15 Provincial Health Services Authority Immunotherapy agents targeting brachyury and methods of using same

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
US5543508A (en) 1987-12-15 1996-08-06 Gene Shears Pty. Limited Ribozymes
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
WO1993001831A1 (en) 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
DE69524105T2 (de) 1994-07-15 2002-07-18 Organon Teknika B.V., Boxtel Verwendung von rna-polymerase zur verbesserung von nukeinsaeure-amplifikationsverfahren
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
JP3907698B2 (ja) 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
EP0814184A4 (en) 1995-02-14 1999-04-14 Chisso Corp BIODEGRADABLE FIBER AND NONWOVEN TEXTILE
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
EP1012276A2 (en) * 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
AU1606799A (en) * 1997-12-09 1999-06-28 Virogenetics Corporation Recombinant vaccinia constructs expressing feline il-2, compositions and methodsof use thereof
JP2003528024A (ja) 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6849255B2 (en) * 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
DE69936868T2 (de) 1998-09-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Page-4, ein gage-ähnliches gen auf dem x-chromosom das von neoplastischer prostata, testis und uterus exprimiert wird, und dessen anwendungen
ATE399179T1 (de) * 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
US20020131976A1 (en) * 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
RU2002103722A (ru) * 1999-07-13 2003-08-27 ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, представл емое СЕКРЕТАРЕМ МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ (US) Белок альтернативной рамки считывания рецептора у Т-клеток(TARP) и его применения
CA2383213A1 (en) 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
US7094408B2 (en) * 2000-04-28 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
AU2002303219A1 (en) * 2001-03-30 2002-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
AU2002330714A1 (en) 2001-05-30 2003-01-02 Biomedical Center In silico screening for phenotype-associated expressed sequences
KR101077177B1 (ko) * 2002-06-06 2011-10-27 온코세라피 사이언스 가부시키가이샤 사람 결장암에 관계하는 유전자 및 폴리펩티드
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JPWO2006004182A1 (ja) * 2004-07-07 2008-04-24 日本電気株式会社 配列予測システム
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Similar Documents

Publication Publication Date Title
JP2014207903A5 (https=)
JP2018148890A5 (https=)
KR102684237B1 (ko) 개인 맞춤형 백신
CA2741724C (en) Promoters for recombinant viral expression
JP7050044B2 (ja) ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2020530303A (ja) Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用
WO2017209053A1 (ja) 新規な遺伝子組換えワクシニアウイルス
CN109844104B (zh) 重组疫苗病毒及其用途
JP2015533841A5 (https=)
SG10201809075XA (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
JP2010259446A5 (https=)
JP2016510989A5 (https=)
JP2010519904A5 (https=)
JP2019535311A5 (https=)
JP2018521651A5 (https=)
JP2019500907A5 (https=)
RU2019112725A (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
CA2909225C (en) Mutant vaccinia virus strains, uses thereof and method of producing the same
JP2023503858A (ja) ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用
JP2021528367A5 (https=)
JP2025500867A (ja) 前立腺癌ワクチン及びその使用
CN103484462B (zh) Survivin启动子调控CD基因的重组腺病毒载体构建及其应用
Lousberg et al. Innate immune recognition of poxviral vaccine vectors
Selmi Oncolytic Viruses: Mechanisms, Engineering Strategies, and Clinical Advances